Webinars, Pharmaceutical

Aptar Pharma supports sustainability journey of pharma manufacturers

In this webinar, experts from Aptar share how they are addressing the challenges of sustainability and the aspirations, goals and targets that can support a more sustainable pharmaceutical industry.
Additionally, Aptar share insights and observations from the field about how a highly regulated market can become more sustainable, what we can learn from other consumer markets such as Food, Beverage and Beauty, and what pioneering solutions will have the potential to change the Pharma business.

Watch the webinar
Speaker(s): Julien Storz Taylor Price Christophe Marie
1 Apr 2022

This Might Also Be of Your Interest

10 Jun 2025

Topical Dermal Drug Delivery System Innovation and Sustainability

Publications, Pharmaceutical, Brand Differentiation, Market Insights, Product Solutions, Sustainability, Drug Delivery Innovations

Read More
21 May 2025

Low GWP pMDI Q&A with Aptar’s ZEN30 Futurity™ Valve Solution

Publications, Pharmaceutical, Market Insights, Product Solutions, Sustainability, Drug Delivery Innovations, Brand Differentiation

Read More
23 Apr 2025

Spotlight on Emissions Reductions for A Lower CO2 Footprint in Pharmaceutical Packagi...

Publications, Pharmaceutical, Sustainability, Brand Differentiation, Market Insights, Product Solutions

Read More
1 Apr 2025

Reducing Pharma’s Scope 3 Emissions with Low GWP pMDIs

Webinars, Pharmaceutical, Market Insights, Product Solutions, Sustainability, Innovation & Insights, Drug Delivery Innovations

Read More
1 2 3 6

Request Access

Close

Requesting access to Aptar Pharma supports sustainability journey of pharma manufacturers.

  • This field is hidden when viewing the form
  • This field is hidden when viewing the form
  • This field is hidden when viewing the form
  • This field is hidden when viewing the form
  • This field is hidden when viewing the form
  • This field is hidden when viewing the form
  • This field is hidden when viewing the form
  • This field is for validation purposes and should be left unchanged.
Back To Top